Page 131 - 南京医科大学自然版

第45卷第5期 卢蓉蓉，瞿 菲，李 薇. 抗体偶联药物用于乳腺癌治疗的耐药机制研究进展［J］.
2025年5月 南京医科大学学报（自然科学版），2025，45（5）：707-717 ·717 ·

with HER2⁃positive，locally advanced or metastatic breast ［44］GARRIDO⁃CASTRO A C，KIM S E，DESROSIERS J，et
cancer：a pooled analysis［J］. Drug Des Devel Ther，2017， al. SACI⁃IO HR ：a randomized phase Ⅱ trial of sacitu⁃
+
11：3235-3244 zumab govitecan with or without pembrolizumab in pa⁃
［36］ANDRE F，HAMILTON E P，LOI S，et al. DESTINY ⁃ tients with metastatic hormone receptor ⁃ positive/HER2 ⁃
Breast07：dose ⁃ expansion interim analysis of T ⁃ DXd negative breast cancer［J］. J Clin Oncol，2024，42（Suppl
monotherapy and T⁃DXd+pertuzumab in patients with pre⁃ 17）：LBA1004
+
viously untreated HER2 mBC［J］. J Clin Oncol，2024，42 ［45］FLYNN P，SURYAPRAKASH S，GROSSMAN D，et al.
（Suppl 16）：1009 The antibody⁃drug conjugate landscape［J］. Nat Rev Drug
［37］PATEL T A，ENSOR J E，CREAMER S L，et al. A ran⁃ Discov，2024，23（8）：577-578
domized，controlled phase Ⅱ trial of neoadjuvant ado ⁃ ［46］KROP I E，MASUDA N，MUKOHARA T，et al. Results
trastuzumab emtansine，lapatinib，and nab⁃paclitaxel ver⁃ from the phase 1/2 study of patritumab deruxtecan，a
sus trastuzumab，pertuzumab，and paclitaxel in HER2 ⁃ HER3⁃directed antibody⁃drug conjugate（ADC），in pa⁃
positive breast cancer（TEAL study）［J］. Breast Cancer tients with HER3 ⁃ expressing metastatic breast cancer
Res，2019，21（1）：100 （MBC）［J］. J Clin Oncol，2022，40（Suppl 16）：1002
［38］FREEDMAN R A，HEILING H M，LI T，et al. Neratinib ［47］YIN Y M，WU X H，OUYANG Q C，et al. Abstract PS08⁃
and ado ⁃ trastuzumab emtansine for pretreated and un⁃ 08：Updated efficacy and safety of SKB264（MK⁃2870）for
treated human epidermal growth factor receptor 2（HER2） previously treated metastatic triple negative breast cancer
⁃ positive breast cancer brain metastases：translational （mTNBC）in phase 2 study［J］. Cancer Res，2024，84
breast cancer research consortium trial 022［J］. Ann On⁃ （Suppl 9）：PS08⁃8⁃PS08⁃08
col，2024，35（11）：993-1002 ［48］WILKS S，CARNEIRO B，COTE G，et al. 762 A first⁃in⁃
［39］JACOBS S A，WANG Y，ABRAHAM J，et al. NSABP human phase 1 clinical study evaluating safety，tolerabili⁃
FB⁃10：a phase Ⅰb/Ⅱ trial evaluating ado⁃trastuzumab ty，pharmacokinetics，pharmacodynamics and efficacy of
emtansine（T⁃DM1）with neratinib in women with metastat⁃ the EDB + FN targeting ADC PYX ⁃ 201 in participants
ic HER2⁃positive breast cancer［J］. Breast Cancer Res， with advanced solid tumors［J］. J ImmunoThera Cancer，
2024，26（1）：69 2023，11（Suppl 1）：A857
［40］HURVITZ S，LOI S，O’SHAUGHNESSY J，et al. Abstract ［49］GUAN J，ZHANG X，WU W W，et al. Abstract LB055：
GS01 ⁃ 10：HER2CLIMB ⁃ 02：randomized，double ⁃ blind IBI3001：a potentially first⁃in⁃class site⁃specifically conju⁃
phase 3 trial of tucatinib and trastuzumab emtansine for gated B7⁃H3/EGFR bispecific ADC for multiple solid tu⁃
previously treated HER2⁃positive metastatic breast can⁃ mors［J］. Cancer Res，2024，84（Suppl 7）：LB055
cer［J］. Cancer Res，2024，84（Suppl 9）：GS01⁃10⁃GS01⁃10 ［50］BONI V，FIDLER M J，ARKENAU H T，et al. Praluzatam⁃
［41］EMENS L A，ESTEVA F J，BERESFORD M，et al. Trastu⁃ ab ravtansine，a CD166 ⁃ targeting antibody ⁃ drug conju⁃
zumab emtansine plus atezolizumab versus trastuzumab gate，in patients with advanced solid tumors：an open⁃la⁃
emtansine plus placebo in previously treated，HER2⁃posi⁃ bel phase Ⅰ/Ⅱ trial［J］. Clin Cancer Res，2022，28（10）：
tive advanced breast cancer（KATE2）：a phase 2，multi⁃ 2020-2029
centre，randomised，double⁃blind trial［J］. Lancet Oncol， ［51］PALACINO J，BAI C，YI Y，et al. Abstract 3933：ORM⁃
2020，21（10）：1283-1295 5029：a first⁃in⁃class targeted protein degradation therapy
［42］SCHMID P，WYSOCKI P，MA C，et al. Abstract PD11⁃ using antibody neodegrader conjugate（AnDC）for HER2⁃
09：PD11⁃09 datopotamab deruxtecan（dato⁃DXd）+ dur⁃ expressing breast cancer［J］. Cancer Res，2022，82（Suppl
valumab（D）as first⁃line（1L）treatment for unresectable 12）：3933
locally advanced/metastatic triple⁃negative breast cancer ［52］ADHIKARI P，ZACHARIAS N，OHRI R，et al. Site⁃spe⁃
（a/mTNBC）：updated results from BEGONIA，a phase 1b/2 cific conjugation to cys⁃engineered THIOMAB TM antibod⁃
study［J］. Cancer Res，2023，83（Suppl 5）：PD11⁃9⁃PD11⁃ ies［J］. Methods Mol Biol，2020，2078：51-69
09 ［53］ZHANG J，JI D M，SHEN W N，et al. Phase I trial of a
［43］SCHMID P，WYSOCKI P J，MA C X，et al. 379MO dato⁃ novel anti ⁃ HER2 antibody ⁃ drug conjugate ，ARX788，
potamab deruxtecan（dato⁃DXd）+ durvalumab（D）as first⁃ for the treatment of HER2 ⁃ positive metastatic breast
line（1L）treatment for unresectable locally advanced/met⁃ cancer［J/OL］. Clin Cancer Res，2022［2022 ⁃ 07 ⁃ 29］.
astatic triple⁃negative breast cancer（a/mTNBC）：updated DOI：10.1158/1078⁃0432.CCR⁃22⁃0456
results from BEGONIA，a phase Ⅰb/Ⅱ study［J］. Ann On⁃ ［收稿日期］ 2024-08-26
col，2023，34：S337 （本文编辑：陈汐敏）